Citigroup Downgrades Integra Lifesciences to Sell, Lowers Price Target to $39
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and lowers the price target from $59 to $39.
May 23, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra Lifesciences downgraded to Sell by Citigroup, with a lowered price target of $39.
Citigroup's downgrade of Integra Lifesciences from Neutral to Sell and the lowering of the price target from $59 to $39 indicates a negative outlook for the stock. This could lead to a short-term decline in the stock price as investors react to the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100